AA
ARIA

AlphaMark Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

AlphaMark Advisors’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-172
Closed -$2K – 484
2016
Q3 		$2K Hold
172
– – ﹤0.01% 329
2016
Q2 		$1K Hold
172
– – ﹤0.01% 330
2016
Q1 		$1K Hold
172
– – ﹤0.01% 313
2015
Q4 		$1K Hold
172
– – ﹤0.01% 303
2015
Q3 		$1K Hold
172
– – ﹤0.01% 289
2015
Q2 		$1K Hold
172
– – ﹤0.01% 294
2015
Q1 		$1K Hold
172
– – ﹤0.01% 297
2014
Q4 		$1K Hold
172
– – ﹤0.01% 291
2014
Q3 		$1K Buy
+172
New +$1K ﹤0.01% 312

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

AlphaMark Advisors's ARIA Position: Q4 2016 in Review

AlphaMark Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 172 shares — an estimated $2K sold.

AlphaMark Advisors first reported a position in ARIA in Q3 2014 and held it in 9 quarters. The position peaked at $2K in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • AlphaMark Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • AlphaMark Advisors sold 172 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $2K.
  • AlphaMark Advisors first reported a position in Ariad Pharmaceuticals Inc in Q3 2014 and held it in 9 quarters.
  • AlphaMark Advisors's Ariad Pharmaceuticals Inc position peaked at $2K in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on AlphaMark Advisors's 13F filing for Q4 2016, filed 26 Jan 2017.